have progressed beyond proof-of-concept studies 1,2,4,8,9 . To address this unmet public 42 health need, we developed a two-antibody cocktail, MBP134 AF , with demonstrable activity 43 against all known ebolaviruses (companion report, Wec et al.), including the "pre-44 emergent" agent Bombali virus recently discovered in molossid bats in Sierra Leone 10 . 45 MBP134 AF , comprising the human bNAbs ADI-15878 AF and ADI-23774 AF , was selected 46 after a systematic process including the assessment and/or optimization of multiple mAbs 47 and their combinations for potency and breadth, Fc effector functions via glycan 48 engineering, and in vivo efficacy in rodent models of EBOV and SUDV infection 49 (companion report, Wec et al.) . ADI-15878 AF and ADI-23774 AF both target unique, non-50 overlapping epitopes on the ebolavirus glycoprotein (GP), neutralize both the extracellular 51 and endosomally cleaved forms of GP, and lack crossreactivity against the secreted GP 52 isoform (sGP) that is abundant in the plasma of infected individuals 6,7 . The exceptional 53 potency of MBP134 AF against guinea pig-adapted EBOV and SUDV (companion report, Wec et al.) warranted continued evaluation in the ferret and NHP large-animal models of 55 ebolavirus challenge to assess its clinical potential. 56
We determined MPB134 AF 's protective efficacy against the wild-type Makona 57 variant of EBOV (EBOV/Makona), SUDV variant Gulu (SUDV/Gulu) and BDBV variant 58
But-811250 (BDBV/But-811250) in the recently established ferret model, which does not 59 require any viral adaptation and recapitulates key hallmarks of human EVD 11-13 . Ferrets 60 challenged intranasally with a lethal dose of EBOV/Makona received two 15-mg doses of 61 MBP134 AF three days apart, with the treatment initiated on either day 2 (ferrets 1-4) or 62 day 3 (ferrets 5-8) post infection (p.i.) ( Fig. 1a) . MBP134 AF fully protected from lethal 63 challenge in both treatment groups and cleared viremia even in ferrets 5-8, which showed 64 signs of active infection by reverse transcription polymerase chain reaction (RT-PCR) 65 prior to treatment (Fig. 1b, c) . Similarly, administration of two 15-mg doses of MBP134 AF 66 on days 3 and 6 (ferrets 1-4) afforded complete protection in ferrets challenged with lethal 67 doses of SUDV/Gulu ( Fig. 1d) or BDBV/But-811250 ( Fig. 1g) and inhibited viral 68 replication ( Fig. 1e-f , 1g-i). Because SUDV/Gulu and BDBV/But-811250 have been 69
shown to be less virulent in ferrets than EBOV/Makona, with a relatively delayed time to 70 peak viremia 12 , we next evaluated MBP134 AF in a lower dose-sparing treatment course 71 of two 5-mg doses given on days 3 and 6 p.i. In this treatment group, ferrets 5-8 72 challenged with SUDV/Gulu displayed high levels of viremia and uniformly succumbed to 73 disease by day 11 p.i. (Fig. 1d-f ). By contrast, ferrets 5-8 challenged with BDBV/But-74 811250 (characterized by the slowest onset of viremia 12 ) were protected by the two 5-mg 75 dose regimen, with reversion of viremia in some animals ( Fig. 1g-i) . MBP134 AF is the first 76 ebolavirus therapeutic to achieve full protection in ferrets against three divergent 77
ebolaviruses. 78
We next evaluated the MBP134 AF cocktail's efficacy in the gold-standard non-79 human primate (NHP) model of Ebola virus challenge. Ten rhesus macaques were 80 randomized into two treatment groups, NHPs 1-4 and NHPs 5-8, and a PBS control 81 group of two animals, and then challenged intramuscularly (i.m.) with 1,000 plaque-82 forming units (PFUs) of the Kikwit variant of EBOV (EBOV/Kikwit). NHPs 1-4 received a 83 single 25-mg/kg dose of MBP134 AF on day 4 p.i., whereas NHPs 5-8 received a more 84 conservative two-dose regimen of 50 mg/kg then 25 mg/kg on days 4 and 7 p.i., 85 respectively. Remarkably, the single 25-mg/kg dose of MBP134 AF completely reversed 86 the onset of EVD and protected NHPs 1-4 from a lethal EBOV/Kikwit exposure ( Fig. 2a) . 87
All animals in this study were confirmed to have had an active EBOV/Kikwit infection via 88
RT-PCR (10 7 -10 10 viral genome equivalents per mL (GEQ/mL)) and plaque assay (10 3 -89 10 6 PFU/mL) prior to treatment on day 4 p.i. (Fig. 2b, c) . These high levels of viremia 90 could nonetheless be reversed by MBP134 AF treatment-viremia in animals from both 91 treatment groups fell below the limit of detection in the plaque assay by day 7 p.i. and in 92 the RT-PCR assay by day 14 p.i. (Fig. 2b, c) . Fever was detected in control animals and 93 in three out of four animals in each treatment group at the time of the first MBP134 AF 94 dosing; however all treated animals returned to normal body temperature by day 10 p.i. 95
Treated animals also maintained substantially lower clinical scores and reduced grade of 96 thrombocytopenia compared to control NHPs ( Fig. 2d-f ). Two animals (NHP-3 and NHP-97 8), one from each treatment group, showed significant signs of EVD-induced liver injury 98 prior to treatment, with elevated C-reactive protein (CRP), alanine aminotransferase 99 (ALT) and aspartate aminotransferase (AST). These and other hallmarks of EVD were 100 significantly reduced post-treatment with MBP134 AF by day 10 p.i. (Fig. 2d- 
i, Extended 101
Data Fig. 1) . Thus, the pan-ebolavirus MBP134 AF cocktail could potently reverse the 102 course of EVD and deliver complete therapeutic protection in NHPs following a lethal 103 EBOV/Kikwit challenge with a single dose of only 25 mg/kg. 104
In the experiments described above, MBP134 AF was produced using a Nicotiana 105 benthamiana (tobacco) plant-based expression system 14,15 . However, because the 106 manufacturing infrastructure for Nicotiana-based products is still limited, we sought to 107 transition MBP134 AF to the well-established Chinese hamster ovary (CHO) cell production 108 platform. Accordingly, we expressed MBP134 AF in a GDP-fucose transporter SLC35C1-109 knockout cell line (CHOK1-AF), which maintains the afucosylated state of MBP134 AF, 16 . 110
Comparative studies indicated that CHOK1-AF-produced MBP134 AF is comparable or 111 even surpasses its plant-produced counterpart in neutralization potential (data not 112 shown), Fc effector functions relevant to this cocktail's antiviral potency (Extended Data 113 Accordingly, all remaining experiments described herein were performed with CHOK1-116 AF expressed MBP134 AF , the manufacturing system being employed for its clinical 117
development. 118
We tested MBP134 AF in a blinded NHP study in which rhesus macaques were 119 challenged i.m. with SUDV variant Boniface (SUDV/Boniface; 1,000 PFU). This model 120 typically affords 50% lethality 17 (unpublished data). Twelve animals were randomized into 121 two treatment groups, NHPs 1-4 and NHPs 5-8, and one control group, PBS controls 1-4. On day 5 p.i., NHPs 1-4 and 5-8 received single 7.5-mg/kg and 25-mg/kg doses of 123 MBP134 AF , respectively. Both doses of MBP134 AF provided full protection from SUDV 124 disease and all MBP134 AF -treated animals became viremia-negative by day 8 p.i. (Fig.  125 3a-c). MBP134 AF -treated animals displayed little to no clinical signs of disease in contrast 126 to the control animals-half of the latter succumbed to infection (Fig. 3d) . Importantly, all 127 of the animals in the blinded MBP134 AF cohort registered a fever prior to receiving 128 MBP134 AF on day 5 p.i. (Fig. 3e) . The two surviving control animals remained viremic 129 past day 14 p.i. (Fig. 3b, c) , maintained elevated ALT, AST, and alkaline phosphatase 130 (ALP) levels, and showed significant thrombocytopenia ( Fig. 3f-i, Extended Data Fig. 4 ) 131 out to day 21 p.i. 132
We next determined the protective efficacy of MBP134 AF against lethal BDBV/But-133 811250 challenge in the cynomolgus macaque model of infection 5, 9 . We chose to treat 134 animals at day 7 p.i. with MBP134 AF because previous reports indicated that they were 135 already viremic and showing signs of EVD at this time point 9 . We reasoned that treatment 136 under these post-exposure conditions would afford a rigorous evaluation of MBP134 AF 's 137 ability to reverse advanced EVD caused by BDBV. 138
Accordingly, a cohort of 9 animals was exposed to 1,000 PFU (i.m.) of BDBV/But-139 811250. Six randomly selected animals received a single 25-mg/kg i.v. infusion of 140 MBP134 AF on day 7 p.i. and three received PBS. This single dose of MBP134 AF provided 141 significant levels of protection (P value of 0.006 or 0.0108 if calculated including the 142 historical controls 9 ), with only one animal succumbing to infection. By contrast, uniform 143 lethality was observed in the PBS control group (Fig. 4a) . Prior to MBP134 AF treatment 144 on day 7 p.i., animals registered elevated clinical scores and body temperatures, viremia 7 as high as ~10 11 GEQ/mL or 10 7 PFU/mL, and EVD-induced thrombocytopenia ( Fig. 4b-146 f). By the next blood collection point, on day 10 p.i., animals that received MBP134 AF had 147 no detectable infectious BDBV in the blood, and clinical scores were reduced to basal 148 levels by day 12 p.i., a complete reversion of infection and disease. The single treated 149 animal that succumbed, NHP-5, did not have the highest viral load but showed acute liver 150 injury prior to treatment, displaying the highest ALP, ALT, and AST levels of all the 151 animals in the cohort on day 7 p.i. prior to receiving its dose of MBP134 AF (Fig. 4g-i,  152 Extended Data Fig. 5) . Given the recovery of two animals (NHP-4 and NHP-6) harboring 153 higher viral loads prior to treatment, we postulate that NHP-5's liver injury prior to 154 treatment was too severe for it to recover despite receiving MBP134 AF . To our knowledge, 155 MBP134 AF is the first therapeutic to demonstrate significant levels of protection and 156 reversion of BDBV disease in cynomolgus macaques. 157
Prior to this work, the development of monoclonal antibody-based therapeutics has 158 typically followed a "one bug, one drug" paradigm under the premise that mAbs with broad 159 activity would not be as potent as those with clade-specific activity 18 . Here, we 160 demonstrate that MBP134 AF , a pan-ebolavirus immunotherapeutic comprising two bNAbs 161 ADI-15878 AF and ADI-23774 AF could not only protect NHPs against every ebolavirus 162 known to cause human disease outbreaks but could do so at an unparalleled single 25-163 mg/kg dose. Importantly, MBP134 AF was effective against multiple ebolaviruses from 164 different species, suggesting that it will retain activity in the face of both intra-and inter-165 species sequence divergence, a result of its targeting highly conserved epitopes in GP. 
